


Cordex expands Zemcelpro access to Hong Kong and Singapore for stem cell transplantation

July 17, 2026 | News

FarmaMondo has been granted distribution rights for Zemcelpro® in Argentina, Hong Kong and Singapore



Canada-based ExCellThera Inc., a global leader in blood stem cell expansion and metabolic fitness technologies and parent company of Cordex Biologics, has announced that Cordex has entered into an agreement granting FarmaMondo SA distribution rights for Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, in Argentina, Hong Kong and Singapore.

Zemcelpro® is a novel personalised cryopreserved hematopoietic stem cell transplantation product containing two cellular components: UM171-expanded CD34+ cells (dorocubicel); and unexpanded CD34- cells, each derived from the same cord blood unit. It is indicated in the European Union for the treatment of adult patients with hematological malignancies requiring allogeneic hematopoietic stem cell transplantation following myeloablative conditioning where no suitable donor is available.

Under the agreement, FarmaMondo will support early access programmes for Zemcelpro® in the agreed territories by leveraging its expertise in regulatory, market access and specialty distribution services for innovative medicines across international and emerging markets.

The agreement is intended to facilitate access to Zemcelpro® for eligible patients through applicable early access pathways in the covered territories.